Navigation Links
S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders
Date:12/2/2009

Treatment was well tolerated. Three patients at the 300mg dose level demonstrated disease response with reductions in the tumor measurements (follicular lymphoma, small lymphocytic lymphoma and mantle cell lymphoma). Overall 11 patients (73%) had stable disease. Preliminary analysis demonstrated that SB1518 inhibited the JAK/STAT pathway as early as four hours after dosing. Collectively, these data demonstrate the safety of chronic administration of the oral JAK2 inhibitor SB1518. Ongoing clinical responses observed in a variety of lymphoma subtypes suggest that targeting the JAK2 pathway may have therapeutic value in patients with relapsed lymphoma.

Poster No.: 1888, Time: 5:30-7:30 p.m. CST, Saturday, Dec. 5, 2009, Location: Hall E (Ernest N. Morial Convention Center)

Pharmacodynamic (PD) Biomarker Assay Validation for SB1518, a Novel Oral JAK2 Inhibitor in Phase 1 Clinical Trials for Advanced Leukemias, Myeloproliferative Diseases and Lymphoma

Biochemical biomarker assays have been developed to assess the pharmacodynamic (PD) efficacy of SB1518 in the Phase 1 clinical trials. Initial data obtained from analysis of whole blood and PBMCs from patients treated with SB1518 in the ongoing Phase 1 clinical trials demonstrate target inhibition even at the lowest dose level of 100 mg/day on the first day of oral dosing.

Poster No. 2913, Time: 6-8 p.m. CST, Sunday, Dec. 6, 2009, Location: Hall E (Ernest N. Morial Convention Center)

The Effects of SB1518, a Novel Oral JAK2 Inhibitor, on Ex Vivo Expanded Polycythemia Vera (PV) Erythroid Progenitors (EPs) Correlate with Clinical Observations

EPs from PV patients and healthy volunteers were treated with SB1518 and other JAK2 inhibitors to determine the effects of JAK2 inhibition on downstream signalling, cell viability and JAK2V617F allele frequency. SB1518 inhibited phospho
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. S*BIO Receives Orphan Drug Designation for JAK2 Inhibitor SB1518 for the Treatment of Myeloproliferative Disorders
2. S*BIO Completes US$26 Million Equity Financing
3. S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317
4. S*BIO Receives BioSpectrum Editors Choice, Emerging BioScience Company of Singapore Award
5. Novel Technology Breaks Through Cancer Pain
6. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
7. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
8. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
9. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
10. NIST team develops novel method for nanostructured polymer thin films
11. GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... are efficient but involve a range of resource ... seed) and pine resin and a clever recycling ... a highly interesting alternative. Their study will be ... . , ,We think our discovery can open ... the batteries of the future, says Daniel Brandell, ...
(Date:9/29/2014)... September 29, 2014 ... "Epigenetics Market by Product (Modifying Enzymes, DNA Polymerase, ... Conversion Kit, Reagents), by Research Area (Developmental ... Forecast to 2019", published by MarketsandMarkets, provides ... restraints, opportunities, current market trends, and strategies ...
(Date:9/29/2014)... (PRWEB) September 29, 2014 ACEA ... Yale University the 2014 iCELLigence Research Grant for ... ACEA’s iCELLigence instrument is an impedance based real-time ... candidate in Department of Biomedical Engineering at Yale ... Chen’s research projects in Professor Rong Fan's ...
(Date:9/29/2014)... Burnham Securities Inc. ("Burnham"), a financial ... leader in healthcare venture development and strategic transactions ... expand the range of services each company can ... Securities will be supported by a team of ... in healthcare industry to build a healthcare franchise. ...
Breaking Biology Technology:Smart, eco-friendly new battery to solve problems 2Epigenetics Market Worth $783.17 Million by 2019 2Epigenetics Market Worth $783.17 Million by 2019 3Epigenetics Market Worth $783.17 Million by 2019 4ACEA Biosciences, Inc. Awards Yale University Researcher the iCELLigence Research Grant 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 2Burnham Securities Inc. and The Channel Group Form Healthcare Alliance 3
... to add new apoA1 measurement and apoB:apoA1 ratio to its, ... ... heart disease, BIRMINGHAM, Ala., Nov. 6 ... its VAP(R),Cholesterol Test in booth No. 2918 at the American Heart ...
... Inc. (Pink,Sheets: SNDY) is pleased to announce that the ... from the St. Mary,s,Hospital in Waterbury, CT. St. Mary,s ... yrs and it has chosen to continue using the,Company,s ... vital role in the history of Greater,Waterbury, providing nearly ...
... Pharmaceuticals, Inc.,(OTC Bulletin Board: ACCP) announced today that it ... Global Investment Conference to be held,November 10-12, 2008 at ... of,Access is scheduled to speak on Tuesday, November 11, ... corporate overview and discuss the Company,s,product opportunities., The ...
Cached Biology Technology:Atherotech to Exhibit VAP(R) Cholesterol Test at American Heart Association Scientific Sessions 2008 2Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Access Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference 2
(Date:9/29/2014)... at Washington State University have concluded that nondigestible ... may help prevent disorders associated with obesity. ... assess these compounds in apple cultivars grown in ... of the journal Food Chemistry ., "We ... source of these nondigestible compounds but there are ...
(Date:9/29/2014)... Behavioral Brain Research provides novel insight into ... of chronic alcohol exposure that can lead to disruptions ... research indicate that individuals with alcohol use disorders frequently ... people are actively drinking, when they are going through ... disturbances can last for months, or even years, after ...
(Date:9/29/2014)... Pangea was starting to break up and dog-sized dinosaurs were ... phytosaurs and rauisuchids were at the top of the food ... didn,t interact much as the former was king of the ... are changing, thanks largely to the contents of a single ... the German journal Naturwissenschaften , Stephanie Drumheller ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2Tooth buried in bone shows prehistoric predators tangled across land, sea 2
... of Oceanography at UC San Diego have developed a ... algae. As reported in this week,s online edition ... Sciences , Scripps graduate student Emily Trentacoste led the ... growth component in biofuel production. In the quest ...
... In what is anticipated to be a major step ... Cell Foundation (NYSCF) Research Institute is partnering with the ... NYSCF scientists will generate stem cell lines from ... researchers to better understand and potentially treat select rare ...
... Smaller bowl sizes may be the next weapon in the battle ... in the Journal of Pediatrics which found children not ... also eat 52 percent more. , "The quickest way parents ... smaller bowl," comments Brian Wansink, professor of behavioral economics and the ...
Cached Biology News:Scripps oceanography researchers engineer breakthrough for biofuel production 2NYSCF and NIH create cell models of rare and undiagnosed diseases 2NYSCF and NIH create cell models of rare and undiagnosed diseases 3
... designed to stabilize the biomolecules during ... There are neither animal proteins ... a convenient 10 times solution in ... to other traditional lyophilizing additives such ...
... benchtop incubator-shaker, has the smallest footprint of all ... 540 x 680 mm (W x D) does ... 505 x 510mm). Available in 25 mm or ... for shaking applications requiring controlled speed and temperature ...
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
... StabilZyme HRP Conjugate Stabilizer is an ... protein and other non-toxic stabilizing chemicals in ... 6.2 6.7. This product contains ... and 20 ppm Proclin 300 (Rohm and ...
Biology Products: